S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
3 tech outperformers adored by analysts
The Battery Metal Nobody Told You About (Ad)
Freshworks gets juiced on its AI customer engagement platform
High short interest stocks: this popular trend is re-emerging
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
Boeing glides past series of setbacks on new flight path
Stock market today: Wall Street inches quietly lower after hitting its 2023 peak last week
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
3 tech outperformers adored by analysts
The Battery Metal Nobody Told You About (Ad)
Freshworks gets juiced on its AI customer engagement platform
High short interest stocks: this popular trend is re-emerging
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
Boeing glides past series of setbacks on new flight path
Stock market today: Wall Street inches quietly lower after hitting its 2023 peak last week
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
3 tech outperformers adored by analysts
The Battery Metal Nobody Told You About (Ad)
Freshworks gets juiced on its AI customer engagement platform
High short interest stocks: this popular trend is re-emerging
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
Boeing glides past series of setbacks on new flight path
Stock market today: Wall Street inches quietly lower after hitting its 2023 peak last week
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
3 tech outperformers adored by analysts
The Battery Metal Nobody Told You About (Ad)
Freshworks gets juiced on its AI customer engagement platform
High short interest stocks: this popular trend is re-emerging
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
Boeing glides past series of setbacks on new flight path
Stock market today: Wall Street inches quietly lower after hitting its 2023 peak last week
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell

Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis

$5.85
-0.16 (-2.66%)
(As of 12/8/2023 08:56 PM ET)
Compare
Today's Range
$5.81
$6.06
50-Day Range
$5.68
$15.21
52-Week Range
$5.53
$34.56
Volume
146,600 shs
Average Volume
164,600 shs
Market Capitalization
$75.99 million
P/E Ratio
4.96
Dividend Yield
N/A
Price Target
$17.00

Eagle Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Sell
1.00 Rating Score
Upside/​Downside
190.6% Upside
$17.00 Price Target
Short Interest
Bearish
5.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.29
Upright™ Environmental Score
News Sentiment
0.66mentions of Eagle Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$295,836 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

149th out of 942 stocks

Pharmaceutical Preparations Industry

49th out of 424 stocks


EGRX stock logo

About Eagle Pharmaceuticals Stock (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

EGRX Stock Price History

EGRX Stock News Headlines

Eagle Pharmaceuticals Shareholder Alert
Eagle Pharmaceuticals Shareholder Notice
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Eagle Pharmaceuticals Ongoing Investor Alert
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Here's what Wall Street expects from Eagle Pharmaceuticals's earnings
Eagle Pharmaceuticals Announces Management Change
Eagle Pharmaceuticals's Earnings: A Preview
Eagle Pharmaceuticals Inc EGRX
Eagle Flies on Patent News
See More Headlines
Receive EGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
12/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EGRX
Fax
N/A
Employees
134
Year Founded
2007

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$17.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+190.6%
Consensus Rating
Sell
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$35.64 million
Pretax Margin
11.33%

Debt

Sales & Book Value

Annual Sales
$316.61 million
Cash Flow
$3.70 per share
Book Value
$17.94 per share

Miscellaneous

Free Float
9,234,000
Market Cap
$75.99 million
Optionable
Optionable
Beta
0.55

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Michael Graves (Age 60)
    Interim Executive Chairman
    Comp: $160k
  • Mr. Brian Joseph Cahill (Age 54)
    Chief Financial Officer
    Comp: $606.06k
  • Mr. Ryan Debski
    Executive VP, General Counsel & Chief Compliance Officer
  • Mr. Daniel O'Connor (Age 43)
    Executive VP, Chief Strategy Officer & Head of Corporate Development
  • Dr. Valentin R. Curt M.D.
    Senior Vice President of Clinical Drug Development
  • Dr. Gaozhong Zhu Ph.D.
    Senior Vice President of Pharmaceutical Development
  • Ms. Debra M. Hussain
    Senior VP & Head of Commercial
  • Mr. Reed McClung
    Executive Vice President of Oncology Business Development














EGRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Eagle Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" EGRX shares.
View EGRX analyst ratings
or view top-rated stocks.

What is Eagle Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 1 year price objectives for Eagle Pharmaceuticals' shares. Their EGRX share price targets range from $17.00 to $17.00. On average, they predict the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 190.6% from the stock's current price.
View analysts price targets for EGRX
or view top-rated stocks among Wall Street analysts.

How have EGRX shares performed in 2023?

Eagle Pharmaceuticals' stock was trading at $29.23 on January 1st, 2023. Since then, EGRX stock has decreased by 80.0% and is now trading at $5.85.
View the best growth stocks for 2023 here
.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 EPS for the quarter, beating the consensus estimate of ($0.44) by $1.00. The specialty pharmaceutical company had revenue of $39.85 million for the quarter, compared to analysts' expectations of $46.70 million. Eagle Pharmaceuticals had a trailing twelve-month return on equity of 6.48% and a net margin of 6.04%. During the same quarter in the previous year, the company earned $0.51 EPS.

What guidance has Eagle Pharmaceuticals issued on next quarter's earnings?

Eagle Pharmaceuticals issued an update on its FY 2023 earnings guidance on Friday, October, 6th. The company provided earnings per share guidance of $4.40-$4.70 for the period, compared to the consensus estimate of $4.58. The company issued revenue guidance of -.

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Schnitzer Steel Industries (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Brandes Investment Partners LP (8.73%), Adage Capital Partners GP L.L.C. (3.85%), AQR Capital Management LLC (2.18%), Smith Graham & Co. Investment Advisors LP (2.10%), Ameriprise Financial Inc. (1.98%) and Acadian Asset Management LLC (1.82%). Insiders that own company stock include Richard A Edlin and Scott Tarriff.
View institutional ownership trends
.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EGRX) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -